A First in Migraine Treatment: FDA Authorizes a Digital Therapy App

Digital Health Has Often Disappointed… Could This Be an Exception?

Over 50 billion dollars has been invested in digital health technologies over the past 15 years. Yet these investments have neither reduced healthcare costs, meaningfully improved patient experience, nor produced truly transformative companies. Many authorities therefore regard digital health as “one of the greatest disappointments of the 21st century.”

Against this background, an FDA decision in April 2025 stands out as a notable exception: Developed for migraine prevention, the mobile app CT-132, became the first prescription digital therapeutic to receive FDA marketing authorization.

However, this distinction matters: It is not “FDA approval,” but the FDA's “de novo” review process that provided marketing authorization. In other words, sufficient evidence of safety and effectiveness in particular patient groups was submitted to permit use in the United States market.

Why Does It Matter?

Migraine is a common neurological condition affecting approximately 1.1 billion people worldwide . This represents approximately 14-15% of the world's population. Migraine is a chronic, neurologically based headache disorder affecting quality of life. Particularly common among young women, it can seriously disrupt social, professional, and personal life. Conventional medicines may not always provide an adequate response or may be poorly tolerated.

What Is CT-132 and Who Was It Developed For?

CT-132, developed by Click Therapeutics , is a scientifically based, smartphone-delivered digital therapy. It targets migraine pain-processing pathways through biological, psychological, and behavioral approaches.

The app's main features include:

• Brief daily behavioral exercises
• Attack tracking with an electronic diary (eDiary)
• Psychoeducational modules and cognitive strategies

The app is designed as an addition to existing acute or preventive migraine treatments ; it is not a stand-alone treatment and is not intended to replace existing therapies.

What Supports Its Reliability? The ReMMi-D and ReMMiD-C Studies

The effectiveness of CT-132 in the phase 3 ReMMi-D study was tested in more than 500 people with episodic migraine, who used either CT-132 or a similar-looking sham app for 12 weeks. The findings were notable:

• Monthly migraine days decreased significantly
• Quality of life improved and disability decreased
• Patient adherence to the app was high

The second study, ReMMiD-C, involved different patient groups receiving CGRP inhibitors and produced similarly positive results. This demonstrates the potential to use digital therapy alongside medication.

What Kind of Authorization Did the FDA Grant?

CT-132 is a digital medical device evaluated under the FDA's “de novo” marketing process and authorized for marketing. This pathway was designed specifically for low- to moderate-risk devices without an equivalent already on the market. Therefore:

• Marketing of CT-132 has been authorized (marketing authorization)
• This is not equivalent to drug approval or approval of a high-risk medical device
• The app does not replace other migraine treatments and should be viewed as complementary.

What Happens Next?

The current name CT-132 is temporary. The app has not yet been commercially launched, and its name is expected to change as launch approaches. In addition, under the FDA's PDURS (Prescription Drug Use-Related Software) guidance, there are plans for the app to be supported by additional claims of clinical benefit in the future.

Conclusion: Digital Therapy Opens a New Chapter in Migraine Care

Marketing authorization for CT-132 opens the door to a new digital era in migraine treatment. It is an important development for patients seeking non-drug support or wishing to strengthen existing treatment. However, these digital therapies should accompany conventional treatment rather than replace it .